Company profile

TolerogenixX

VZP0468 | Baden-W├╝rttemberg

TolerogenixX has an innovative cell technology that can be used to suppress unwanted immune responses in the body. This novel cell therapy will revolutionize the treatment of transplant recipients and numerous autoimmune diseases. The unique feature of the TolerogenixX method is the simple modification of white blood cells by use of the TolerogenixX therapy kit. Once infused, these modified cells suppress unwanted immune responses in the patient┬┤s body. The first patients have already been successfully treated in a phase-I clinical study in kidney transplantation. Due to the promising results from the phase I study, there are already preparations for the TOL-2 phase II study.

Business Model

Technology Development

Industry

  • Life Science & Healthcare

Customer Focus

B2B

Registered Office

Im Neuenheimer Feld 162
69120 Heidelberg
Germany

Contact